AP-T: The ratio of serum thyroxine T3 to thyroxine T4 (T3 / T4) predicts the therapeutic effect of biotherapy in elderly IBD patients

BACKGROUND: The incidence of inflammatory bowel disease (IBDs) in old age is increasing, and older people have different responses to current drug treatment options than young people, so additional biomarkers are needed to optimize their treatment.
we know that the ratio of serum triiodine thyroxine to thyroxine (T3 / T4) is associated with weakness in older patients.
, this study aims to assess the suitability of the T3/T4 ratio as an indicator of the response of older IBD patients to biologics.
method: The researchers plan to evaluate treatment outcomes after 54 weeks of treatment for elderly IBD patients who started using biologics, including mucous membrane healing (Mayo endoscopic score for ulcerative colitis - 2; crohn's disease ulcer disappearance) and clinical remission (partial Mayo score for ulcerative colitis . . . .
researchers evaluated the T3/T4 ratio at baseline and tested its association with treatment results using multivariate logistic regression and subject work characteristics (ROCs).
results The study eventually recruited a total of 80 patients; 44 cases of clinical remission and 36 cases of mucosal healing.
The baseline T3/ T4 ratio was higher in patients with mucous membrane healing than in patients without mucous membrane healing (P.lt;0.0001), regardless of disease type or biological drug (T3 / T4 increased by 1 OR 6.4 (2.9-14.3), P.lt;0.0001).
threshold 3.3 is determined to be the optimal baseline T3/T4 ratio threshold for predicting mucous membrane healing, and such truncation values provide 78% sensitivity and 89% specificity (area under ROC curve 0.88 (0.79-0.94).
T3/ T4 ratio is a reliable tool for predicting the results of biological therapy in elderly IBD patients, and can predict the efficacy of elderly IBD patients at an early stage.